To Our Shareholders
For providing high value-added,
“Growth” and “Progress” never stop.
We wish to express our gratitude to all our shareholders for your continuing
support.
The Group is advancing the Medium-Term Management Plan “SHIP VISION 2024.” As the second
term (the fiscal year ended 31 March 2024), we had steadily advanced the steps of our “Growth” and
“Progress” through operating high value-added business.
Consolidated financial results of the year and return of profits:
Continuing to maintain the basis of an increase in sales and profit.
The sales growth for the 24 consecutive years, before listing.
Despite the impact of political instability in Myanmar on the Total Pack Produce business,
domestic project operations proceeded steadily as planned. The increase in treatment cases at
the heavy ion cancer treatment facility, along with the performance of the Kingrun Group (which
joined our group in July 2022) being accounted for from the beginning of the fiscal year,
contributed to a solid increase in both sales and profits. Additionally, the Medical Supply
business, Life Care business, and Pharmacy business also progressed steadily, contributing to
increased sales and profits.
As a result, consolidated financial results of the year achieved an increase in sales and profit
of two digits; net sales is 630.9 billion yen (increased 10.3% YoY), operating profit is 24.5
billion yen (increased 16.0% YoY) and profit attributable to owners of parent is 13.7 billion
yen (increased 14.3% YoY).
Considering these business trends, we have decided to further increase dividends for
shareholders beyond our initial forecast. As a consequence, dividends per share is 50 yen, an
increase of 8 yen from the previous year, consisting of 45 yen of ordinary dividend and 5 yen of
commemorative dividend of 30th anniversary. This marks the eighth consecutive year of dividend
increases. We will continue to aim for a payout ratio of 30% or more and strive to distribute
profits in line with the growth of our performance.
Financial results
(million yen) | FY03/2023 (previous year) |
FY03/2024 (this year) |
YoY change |
---|---|---|---|
Net sales | 572,285 | 630,988 | + 10.3% |
Operating profit | 21,144 | 24,535 | + 16.0% |
Ordinary profit | 20,607 | 25,215 | + 22.4% |
Profit attributable to owners of parent | 12,063 | 13,789 | + 14.3% |
Progress of Medium-Term Business Plan
Our challenge, creating new values for regional healthcare, has steadily progressed
We are making steady progress towards achieving the medium-term business plan, focusing on four
important measures set forth at its inception” Further growth of core business”,” Further expand
value”,” Functional enhancement strategy” and “Activities for sustainability”. Concretely,
starting from “consulting capabilities” and “producing capabilities”, which exploiting various
know-how of whole Group, we continue to expand the circle of providing high quality and
wide-ranging value to regional healthcare.
In the Total Pack Produce business, we have undertaken distinctive projects such as the
integration of two hospitals, one is public and the other is private, into the regional core
hospital, Kawanishi City Medical Center(relocated and opened in September 2022)under the concept
of “Empower local medical systems in Japan”, and AILE HOME CLINIC NAGAOKA(established in
September 2023) as an urban redevelopment project in front of the Nagaoka station in Niigata
prefecture, which aims to “contribution to urban development from medical care”. “Creating
environments for medical professionals”, we take initiative, proceeded into a new stage with
engaging various projects with brand new concepts.
In addition, as part of the Well-being business, we have secured comprehensive management
operations regarding in total of 84 facilities, including elementary schools, junior high
schools, kindergartens and nursery schools etc., which under jurisdiction of Suita city, Osaka
(The contract term is 5 years, from 2023 to 2028).
In the Medical Supply business, we are particularly focused on “strengthening efforts for
medical DX” . In the field of medical in Japan, under the leadership of “Headquarters for
Medical Digital Transformation (DX) Promotion” which Japanese Government newly established, DX
is promoted towards streaming services and improving quality. Our group anticipates these
movements, proceed visualization of SPD date in medical facilities all over Japan and engage in
initiatives for creating future medical service basis by Industry, Government, and
Academia(including participating in “The Cross- ministerial Strategic innovation Promotion
program”, which Cabinet office takes initiatives and supporting for “The Medical AI and Digital
Twin Development Course” in the University of Tokyo).
Challenges for creating new value for regional healthcare led to the coexistence of certain
social contribution and improvement of corporate values, leading us towards the long-term goal
of achieving a consolidated net sales of one trillion yen.
We sincerely appreciate all of you for your continued support and encouragement.